Moderate-to-severe plaque psoriasis patients treated with ixekizumab: early real-world outcomes and adverse events-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Moderate-to-severe plaque psoriasis patients treated with ixekizumab: early real-world outcomes and adverse events

Published:2020-04-22 Issue: Volume: Page:1-7
ISSN:0954-6634
Container-title:Journal of Dermatological Treatment
language:en
Short-container-title:Journal of Dermatological Treatment

Author:

Gulliver Wayne¹²,Penney Michelle²,Power Rebecca¹²,Gulliver Susanne²,Montmayeur Sonia³,Burge Russel³⁴

Affiliation:

1. Faculty of Medicine, Memorial University of Newfoundland, St. John’s, Canada;

2. Newlab Clinical Research Inc, St. John’s, Canada;

3. Eli Lilly and Company, Indianapolis, IN, USA;

4. Division of Pharmaceutical Sciences, Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA

Publisher

Informa UK Limited

Subject

Dermatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/09546634.2020.1755009

Reference23 articles.

1. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey

2. Pharmacotherapeutic approaches for treating psoriasis in difficult-to-treat areas

3. The Emerging Role of IL-17 in the Pathogenesis of Psoriasis: Preclinical and Clinical Findings

4. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

5. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis;Drugs;2024-04-17

2. Effectiveness of biologic treatment for psoriasis in Malaysia: Real-world evidence and review of current evidence from Southeast Asia;Dermatologica Sinica;2024-04

3. Advantages of IL-17 inhibitor, ixekizumab, in the treatment of severe psoriasis;Meditsinskiy sovet = Medical Council;2024-03-08

4. Bio‐experienced psoriasis patients treated with anti‐interleukin monoclonal antibodies are less likely to achieve PASI 90, PASI 100, PASI ≤ 1 and ≤3: Results from a cohort of 305 patients;JEADV Clinical Practice;2023-10-09

5. Ixekizumab is effective in the long-term management in moderate-to-severe plaque psoriasis: results from an Italian retrospective cohort study (the LOTIXE study);Journal of Dermatological Treatment;2023-08-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3